Cardiovascular and renal treatment in patients with heart failure with hyperkalemia or at high risk of hyperkalemia (CARE-HK in the HF registry)
COMMERCIAL POST AUTHORIZATION STUDY
Clinical trial information
- Promoter: VIFOR (INTERNATIONAL) INC.
- Execution start: 08/02/2022
- End of execution: 30/04/2025
- IP: SILVIA LOPEZ FERNANDEZ